About us
Fenlai Tan, MD, PhD
CEO
Specialized in the clinical development and commercialization of anticancer drugs, authored over 60 papers in prestigious academic journals, including Lancet Oncology and hold more than 20 patents.
As a Co-Founder, Board Member, Senior Vice President and CMO at Betta Pharmaceutical Company, successfully spearheaded the clinical development, strategic in-licensing, and NDA for 4 anticancer drugs, including Icotinib, as well as in-licensed Ensartinib, Vorolanib and Bevacizumab, which has significantly benefitted numerous patients since their market introduction.
Currently leading the clinical development and global commercialization for all ongoing programs.